Steven J. Burakoff

Steven J. Burakoff is a cancer specialist and the author of both Therapeutic Immunology (2001) and Graft-Vs.-Host Disease: Immunology, Pathophysiology, and Treatment (1990). He served as Director of The Tisch Cancer Institute at Mount Sinai (2007-2017), which was created in 2007 to focus on translational medicine. He is the Lillian and Henry M. Stratton Professor of Cancer Medicine at Mount Sinai Medical Center as well as Dean for Cancer Innovation and Chief, Pediatric Oncology at the Icahn School of Medicine.

Biography
Before joining Mount Sinai, he was recruited by New York University School of Medicine to revitalize the research and treatment mission of NYU's Cancer Institute, which during his tenure experienced a 31 percent growth and a 50 percent increase in funding from the National Cancer Institute. He completed a residency in medicine at New York Hospital-Cornell Medical Center and pursued fellowships in immunology at both Rockefeller University and Harvard Medical School.

He has received 84 grants as of 2020 in fields related to core administration, cancer, T-Cell activation and regulation, as well as various immunological studies.

His brother, Robert Burakoff, is a gastroenterologist at Brigham and Women's Hospital in Boston, MA.

Awards

 * 1995 Harvard Medical School Excellence in Mentoring Award
 * 2006 Lynne Cohen Foundation Award
 * 2009 American Association of Immunologists Lifetime Achievement Award
 * 2019 Elected a Distinguished Fellow of American Association of Immuologists

Appointments and positions

 * Director of The Tisch Cancer Institute at Mount Sinai
 * Past Director, Skirball Institute of Biomolecular Medicine, New York University School of Medicine
 * Board of Directors, Pharmacopeia Drug Discovery, Inc.
 * Board of Directors, Damon Runyon Cancer Research Foundation

Publications
Burakoff has published 404 articles as of 2020 and has been cited more than 23,000 times according to RearchGate.

Books

 * Strom TB, Austen KF, Burakoff SJ. Therapeutic Immunology. Wiley-Blackwell, 2001 ISBN 0-632-04359-8
 * Ferrara JLM, Deeg HJ, Burakoff SJ. Graft-Vs.-Host Disease: Immunology, Pathophysiology, and Treatment. Marcel Dekker, 1990 ISBN 0-8247-9728-0

Other publications (partial list)

 * Interleukin-3 (IL-3)-induced c-fos activation is modulated by Gab2-calcineurin interaction. Pyarajan S, Matejovic G, Pratt JC, Baksh S, Burakoff SJ. Journal of Biological Chemistry. 2008
 * Lysine 144, a ubiquitin attachment site in HIV-1 Nef, is required for Nef-mediated CD4 down-regulation. Jin YJ, Cai CY, Zhang X, Burakoff SJ. Journal of Immunology 2008
 * Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway. Sawasdikosol S, Pyarajan S, Alzabin S, Matejovic G, Burakoff SJ. Journal of Biological Chemistry, 2007
 * From bytes to bedside: data integration and computational biology for translational cancer research. Mathew JP, Taylor BS, Bader GD, Pyarajan S, Antoniotti M, Chinnaiyan AM, Sander C, Burakoff SJ, Mishra B. PLoS Computational Biology, 2007
 * A CD8/Lck transgene is able to drive thymocyte differentiation. Fragoso RC, Pyarajan S, Irie HY, Burakoff SJ. Journal of Immunology, 2006
 * HIV Nef-mediated CD4 down-regulation is adaptor protein complex 2 dependent. Jin YJ, Cai CY, Zhang X, Zhang HT, Hirst JA, Burakoff SJ. Journal of Immunology, 2005
 * CD4 phosphorylation partially reverses Nef down-regulation of CD4. Jin YJ, Zhang X, Boursiquot JG, Burakoff SJ. Journal of Immunology, 2004
 * Nicotine activates nuclear factor of activated T cells c2 (NFATc2) and prevents cell cycle entry in T cells. Frazer-Abel AA, Baksh S, Fosmire SP, Willis D, Pierce AM, Meylemans H, Linthicum DS, Burakoff SJ, Coons T, Bellgrau D, Modiano JF. Journal of Pharmacology and Experimental Therapeutics, 2004
 * SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness. Friedman JS, Lopez MF, Fleming MD, Rivera A, Martin FM, Welsh ML, Boyd A, Doctrow SR, Burakoff SJ. Blood, 2004
 * Fratricide of CD8+ cytotoxic T lymphocytes is dependent on cellular activation and perforin-mediated killing. Su MW, Pyarajan S, Chang JH, Yu CL, Jin YJ, Stierhof YD, Walden P, Burakoff SJ. European Journal of Immunology, 2004
 * Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model. Friedman JS, Alpdogan O, van den Brink MR, Liu C, Hurwitz D, Boyd A, Kupper TS, Burakoff SJ. Journal of the American Society of Blood and Marrow Transplantation, 2004
 * Rapamycin-resistant proliferation of CD8+ T cells correlates with p27kip1 down-regulation and bcl-xL induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity. Slavik JM, Lim DG, Burakoff SJ, Hafler DA., Journal of Biological Chemistry, 2004